Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQL1055 with acellular pertussis vaccine safety study
NCT04793620Phase 1Terminated
- Sponsor
- Adjuvance Technologies
- Start
- Apr 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TQL-1055 in pertussis (2 arms), sponsored by Adjuvance Technologies. Primary endpoint: Reactogenicity at 7 days. Started Apr 2021; status: terminated.
02
Drugs
TQL-1055
03
Conditions
pertussis
Beyond the preview
Go deeper on NCT04793620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04793620.